| Literature DB >> 22168500 |
Jessica Carmen1, Scott R Burger, Michael McCaman, Jon A Rowley.
Abstract
A major challenge to commercializing cell-based therapies is developing scalable manufacturing processes while maintaining the critical quality parameters (identity, potency, purity, safety) of the final live cell product. Process development activities such as extended passaging and serum reduction/elimination can facilitate the streamlining of cell manufacturing process as long as the biological functions of the product remain intact. Best practices in process development will be dependent on cell characterization; a thorough understanding of the cell-based product. Unique biological properties associated with different types of cell-based products are discussed. Cell characterization may be used as a tool for successful process development activities, which can promote a candidate cell therapy product through clinical development and ultimately to a commercialized product.Mesh:
Year: 2012 PMID: 22168500 DOI: 10.2217/rme.11.105
Source DB: PubMed Journal: Regen Med ISSN: 1746-0751 Impact factor: 3.806